Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. associated person Michael Brophy filed a notice of proposed sale of 1,178 shares of common stock, to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, with the stock listed on NASDAQ. The shares relate to Restricted Stock Units dated 07/26/2026. The filing also lists recent sales of Natera common stock over the past three months, including 3,070 shares on 04/29/2026, 313 shares on 05/01/2026, 482 shares on 05/04/2026, and 782 shares on 07/27/2026, several executed under a Rule 10b5-1 sales plan.
Jonathan Sheena filed a notice to sell common stock of NTRA, indicating a planned sale of 188 shares on 07/28/2026 with an aggregate value of $48,509.64 through a NASDAQ broker. The shares relate to 6,208 Restricted Stock Units granted on 01/27/2023 for services rendered. The disclosure also lists multiple prior common‑stock sales over the past three months, each with disclosed share counts and dollar amounts.
Daniel Rabinowitz filed a Form 144 indicating an intention to sell 988 shares of Natera common stock, with an aggregate market value of $254,933.64, on or after July 28, 2026 on NASDAQ. The filing notes earlier acquisition of 31,040 restricted stock units on January 27, 2023 for services rendered.
It also lists recent sales of Natera common stock by Rabinowitz, including 33,600 shares for $8,455,352.64 on June 24, 2026 and 16,800 shares for $4,574,430 on July 1, 2026, along with several smaller transactions from April through July 2026.
Solomon Moshkevich filed a notice of proposed sale of 1,185 shares of common stock on NASDAQ, with an indicated value of $305,765.55 and a proposed sale date of 07/28/2026. The securities relate to Restricted Stock Units granted on 01/27/2023 for services rendered, covering 37,248 units.
The filing also lists prior sales of common stock during the past three months, including 3,000 shares on 07/01/2026 for $818,710.5 and several additional transactions between 04/27/2026 and 07/27/2026.
Natera, Inc. insider John Fesko plans to sell 917 shares of common stock on or about 07/28/2026 on the NASDAQ, with an indicated aggregate value of $236,613.51. The securities relate to Restricted Stock Units granted on 01/27/2023 for services rendered.
Over the prior three months, Fesko reported additional common stock sales of 1,688 shares on 04/27/2026 for $344,516.88, 291 shares on 05/01/2026 for $59,992.56, 1,438 shares on 05/26/2026 for $291,683.56, and 782 shares on 07/27/2026 for $203,703.79.
Steven Chapman, an affiliate of the issuer, filed a notice of proposed sale of common stock. The filing lists 3,525 shares of common stock to be sold through a broker, with an aggregate market value of $909,555.75, to be sold on or after July 28, 2026 on NASDAQ.
The security relates to Restricted Stock Units granted on January 27, 2023 in respect of services rendered, covering 127,265 units. The filing also reports prior sales of common stock during the past three months by Steven Chapman, including transactions on April 27, May 1, June 4, and July 27, 2026.
Insider Michael Brophy filed a notice to sell common stock of the issuer, with the securities table showing 1,222 shares of common stock and related numerical figures including 315,312.66 and 143,215,382. The notice references common stock acquired from Restricted Stock Units granted on 01/27/2023 for services rendered. It also lists several prior sales of common stock during the past three months, including 3,070 shares on 04/29/2026 for $594,789.17 and other smaller trades in April, May, and July 2026.
An affiliate of NTRA has filed a notice to sell 285 shares of common stock, with a proposed aggregate sale price of $74,667.15, expected on July 27, 2026. The filing also references a prior grant of 9,405 Restricted Stock Units for services rendered on January 26, 2024 and lists multiple common stock sales by Jonathan Sheena over the past three months.
An affiliate of NTRA has filed a Form 144 indicating an intent to sell common stock acquired from Restricted Stock Units granted for services rendered. The notice covers up to 68,976 shares, and lists several recent sales of common stock over the prior three months.
An affiliate of NTRA reporting person Daniel Rabinowitz filed a notice of proposed sale of 873 shares of common stock, with an aggregate market value of $228,717.27, to be sold through a broker on NASDAQ on 07/27/2026. The filing notes these shares relate to Restricted Stock Units originally acquired on 01/26/2024 for services rendered, in a grant of 27,433 units. It also discloses prior sales of common stock over the past three months in several transactions by Rabinowitz.